Develops monoclonal antibodies for inflammatory respiratory diseases.
Jun 2026Revenue $3.16M/yrExpenses $173M/yr
No trendCash runway ≈ 1.9 years from Jun 2026
Figures by year
When will Upstream Bio be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $3.16M and expenses $173M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $2.85M | $163M | −$160M |
| Dec 2024 | $2.37M | $80.1M | −$77.8M |
| Dec 2023 | $2.38M | $42.5M | −$40.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.